Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ursolic acid nanoliposome
- Development stage
- Phase 1
- Lead developer
- Wuhan Liyuanheng Pharmaceutical Technology
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Ursolic acid nanoliposome is an investigational liposomal formulation of ursolic acid, a naturally occurring pentacyclic triterpenoid, developed by Wuhan Liyuanheng Pharmaceutical Technology. Ursolic acid exhibits significant anti-tumor activity but is limited by poor aqueous solubility and low bioavailability. The nanoliposomal delivery system is designed to enhance the pharmacokinetic profile, improve solubility, and increase tumor-site accumulation of the drug. Mechanistically, ursolic acid induces apoptosis and inhibits tumor cell proliferation, angiogenesis, and metastasis by modulating multiple signaling pathways, including the inhibition of Nuclear factor kappa B (NF-κB) and STAT3, and the activation of the mitochondrial apoptotic pathway through caspase activation and regulation of Bcl-2 family proteins. It has been evaluated in Phase I clinical trials in China for patients with advanced solid tumors, specifically targeting hepatocellular carcinoma, gastric cancer, and colorectal cancer.
- Other names
- ursolic acid liposomenanoliposomal ursolic acidursolic acid nanoliposomes
02
Targets
BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)CASP9 (Caspase-9)STAT3 (Signal Transducer and Activator of Transcription 3)NF-κB
Beyond the preview
Go deeper on ursolic acid nanoliposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ursolic acid nanoliposome.